Arachidonic acid modulates the crosstalk between prostate carcinoma and bone stromal cells

Endocrine-Related Cancer

Volumn 15, Issue 1, 2008, Pages 91-100

  Angelucci, Adriano ^a   Garofalo, Stefania ^a   Speca, Silvia ^a   Bovadilla, Antonella ^a   Gravina, Giovanni Luca ^a   Muzi, Paola ^a   Vicentini, Carlo ^a   Bologna, Mauro ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; FATTY ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; LINOLEIC ACID; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; AUTOCRINE EFFECT; BONE MARROW; BONE METASTASIS; CANCER CELL; CANCER PATIENT; CANCER RISK; CELL COUNT; CELL CULTURE; CELL FUNCTION; CELL SURVIVAL; DRUG POTENTIATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; OSTEOBLAST; PARACRINE SIGNALING; PROSTATE CARCINOMA; PROTEIN EXPRESSION; STROMA CELL;

ARACHIDONATE 5-LIPOXYGENASE; ARACHIDONIC ACID; BLOTTING, WESTERN; BONE MARROW; BREAST NEOPLASMS; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; CYCLOOXYGENASE 2; DNA PRIMERS; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; INTERLEUKIN-1BETA; MALE; PROSTATIC NEOPLASMS; RANK LIGAND; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STROMAL CELLS; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 41349117825     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-07-0100     Document Type: Article

References (26)

1. Angelucci A, Gravina GL, Rucci N, Millimaggi D, Festuccia C, Muzi P, Teti A, Vicentini C & Bologna M 2006 Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocrine-Related Cancer 13 197-210.
2. Brown MD, Hart CA, Gazi E, Bagley S & Clarke NW 2006 Promotion of prostatic metastatic migration towards human bone marrow stoma by Omega 6 and its inhibition by Omega 3 PUFAs. British Journal of Cancer 94 842-853.
3. Burkhardt R, Kettner G, Bohm W, Schmidmeier M, Schlag R, Frisch B, Mallmann B, Eisenmenger W & Gilg T 1987 Changes in trabecular bone, hematopoiesis and bone marrow vessels in aplastic anemia, primary osteoporosis, and old age: a comparative histomorphometric study. Bone 8 157-164.
4. Ciapetti G, Ambrosio L, Marietta G, Baldini N & Giunti A 2006 Human bone marrow stromal cells: in vitro expansion and differentiation for bone engineering. Biomaterials 27 6150-6160.
5. Cuendet M & Pezzuto JM 2000 The role of cyclooxygenase and lipoxygenase in cancer chemoprevention. Drug Metabolism and Drug Interactions 17 109-157.
6. Furstenberger G, Krieg P, Muller-Decker K & Habenicht AJ 2006 What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis? International Journal of Cancer 119 2247-2254.
7. Gamradt SC, Feeley BT, Liu NQ, Roostaeian J, Lin YQ, Zhu LX, Sharma S, Dubinett SM & Lieberman JR 2005 The effect of cyclooxygenase-2 (COX-2) inhibition on human prostate cancer induced osteoblastic and osteolytic lesions in bone. Anticancer Research 25 107-115.
8. Ghosh J & Myers CE Jr 1998a Arachidonic acid metabolism and cancer of the prostate. Nutrition 14 48-49.
9. Ghosh J & Myers CE 19986 Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. PNAS 95 13182-13187.
10. Gugliucci A, Ranzato L, Scorrano L, Colonna R, Petronilli V, Cusan C, Prato M, Mancini M, Pagano F & Bernardi P 2002 Mitochondria are direct targets of the lipoxygenase inhibitor MK886 A strategy for cell killing by combined treatment with MK886 and cyclooxygenase inhibitors. Journal of Biological Chemistry 277 31789-31795.
11. Hassan S & Carraway RE 2006 Involvement of arachidonic acid metabolism and EGF receptor in neurotensin-induced prostate cancer PC3 cell growth. Regulatory Peptides 133 105-114.
12. Kitaura H, Sands MS, Aya K, Zhou P, Hirayama T, Uthgenannt B, Wei S, Takeshita S, Novack DV, Silva MJ et al. 2004 Marrow stromal cells and osteoclast precursors differentially contribute to TNF-alpha-induced osteoclastogenesis in vivo. Journal of Immunology 173 4838-4846.
13. Kitaura H, Zhou P, Kim HJ, Novack DV, Ross FP & Teitelbaum SL 2005 M-CSF mediates TNF-induced inflammatory osteolysis. Journal of Clinical Investigation 115 3418-3427.
14. Kobayashi N, Barnard RJ, Henning SM, Elashoff D, Reddy ST, Cohen P, Leung P, Hong-Gonzalez J, Freedland SJ, Said J et al. 2006 Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clinical Cancer Research 12 4662-4670.
15. Madaan S, Abel PD, Chaudhary KS, Hewitt R, Stott MA, Stamp GW & Lalani EN 2000 Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. BJU International 86 736-741.
16. Moretti RM, Montagnani Marelli M, Sala A, Motta M & Limonta P 2004 Activation of the orphan nuclear receptor RORalpha counteracts the proliferative effect of fatty acids on prostate cancer cells: crucial role of 5-lipoxygenase. International Journal of Cancer 112 87-93.
17. Nuttall ME, Patton AJ, Olivera DL, Nadeau DP & Gowen M 1998 Human trabecular bone cells are able to express both osteoblastic and adipocytic phenotype: implications for osteopenic disorders. Journal of Bone and Mineral Research 13 371-382.
18. Parkar BA, McCormick ME & Foster SJ 1990 Leukotrienes do not regulate interleukin 1 production by activated macrophages. Biochemical and Biophysical Research Communications 169 422-429.
19. Riendeau D, Percival MD, Brideau C, Charleson S, Dube D, Ethier D, Falgueyret JP, Friesen RW, Gordon R, Greig G et al. 2001 Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. Journal of Pharmacological and Experimental Therapeutics 296 558-566.
20. Rose DP 1997 Effects of dietary fatty acids on breast and prostate cancers: evidence from in vitro experiments and animal studies. American Journal of Clinical Nutrition 66 1513S-1522S.
21. Terry PD, Rohan TE & Wolk A 2003 Intakes of fish and marine fatty acids and the risks of cancers of the breast and prostate and of other hormone-related cancers: a review of the epidemiologic evidence. American Journal of Clinical Nutrition 77 532-543.
22. Tokuda Y, Satoh Y, Fujiyama C, Toda S, Sugihara H & Masaki Z 2003 Prostate cancer cell growth is modulated by adipocyte-cancer cell interaction. BJU International 91 716-720.
23. Vessella RL & Corey E 2006 Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis. Clinical Cancer Research 12 6285s-6290s.
24. Wang Y, Corr JG, Thaler HT, Tao Y, Fair WR & Heston WD 1995 Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. Journal of National Cancer Institute 87 1456-1462.
25. Wynder EL, Rose DP & Cohen LA 1994 Nutrition and prostate cancer: a proposal for dietary intervention. Nutrition and Cancer 22 1-10.
26. Yoneda T & Hiraga T 2005 Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochemical and Biophysical Research Communications 328 679-687.